CD19 and B-cell non-Hodgkin lymphoma: The development of CD19-directed chimeric antigen receptor T-cell therapy (CD19 CART) altered the treatment landscape for patients with relapsed or refractory (R/R) B-cell NHLs as it provides a new option for patients who previously had limited other effective alternatives (2).